Skip to content

Study · Measured the body's own peptide · 1989

3 results

Coexistence of delta sleep-inducing peptide and serotonin in midgut carcinoid tumour cells in vivo and in vitro.

Ahlman H, Ahlund L, Nilsson O, Dahlström A, Bjartell A, Ekman R

International journal of cancer1 Oct 1989Cited by 2 (Europe PMC)

PMID2793237 (opens in a new tab)DOI10.1002/ijc.2910440414 (opens in a new tab)PepBankPUB-02793237
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In midgut carcinoid tumour biopsies, immunocytochemistry showed natural DSIP coexisting with serotonin in most tumour cells studied.

    In plain wordsIn midgut carcinoid tumour samples, the body's own DSIP was found in the same cells as serotonin in most cells studied.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    Not applicableDSIP and serotonin coexistence in carcinoid tumour cells
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    By immunocytochemistry, delta sleep-inducing peptide (DSIP) was demonstrated to coexist with serotonin (5-HT) in a majority of midgut carcinoid tumour cells studied in biopsies and long-term cell cultures.

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with midgut carcinoid syndrome, pentagastrin provocation raised peripheral serotonin levels but not DSIP levels.

    In plain wordsIn patients with midgut carcinoid syndrome, a pentagastrin test raised blood serotonin but did not change the body's own DSIP levels.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changePeripheral DSIP level after pentagastrin provocation
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Provocation with pentagastrin in patients with midgut carcinoid syndrome resulted in increased peripheral levels of 5HT, but not of DSIP.

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  3. 03LabEndogenous levelIn vitro (cells)Other

    Cultures of midgut carcinoid tumour cells produced several DSIP-like peptides that were separated chromatographically from the culture media.

    In plain wordsIn cells grown from carcinoid tumours, the cells themselves made several DSIP-like peptides, the body's own kind.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    Not applicableDSIP-like peptide production by carcinoid cell cultures
    Study

    n: not reported in source

    Long-term cultures of midgut carcinoid tumour cells
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    The cultures produced several DSIP-like peptides chromatographically separated from culture media.
    1 context sentence
    Summary · context
    By immunocytochemistry, delta sleep-inducing peptide (DSIP) was demonstrated to coexist with serotonin (5-HT) in a majority of midgut carcinoid tumour cells studied in biopsies and long-term cell cultures.

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.